CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. We show 39 historical shares outstanding datapoints in our CTMX shares outstanding history coverage, used to compute CTMX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CTMX market cap history over the course of time is important for investors
interested in comparing CTMX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CTMX versus a peer is one thing; comparing
CTMX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CTMX can fluctuate over the course of history.
With this page we aim to empower investors researching CTMX by allowing them to research the CTMX market cap history. |
Free CTMX Email Alerts:
Video: The Importance of Market Cap
